As flu sea­son emerges, BD com­pletes sy­ringe man­u­fac­tur­ing lines with help from US gov­ern­ment; Hot off sum­mer­time de­but on NYSE, con­struc­tion on Ste­vana­to's mid­west site be­gins

BD has upped the US gov­ern­ment’s ac­cess to safe­ty in­jec­tion de­vices through the in­vest­ment of two new sy­ringe and nee­dle man­u­fac­tur­ing lines.

The com­pa­ny com­plet­ed con­struc­tion of the lines on a sped-up time­line through a part­ner­ship with the US De­part­ment of Health and Hu­man Ser­vices. BAR­DA in­vest­ed $42 mil­lion in­to the rough­ly $70 mil­lion project to add lines in Hol­drege, NE.

“As the fight against COVID-19 con­tin­ues, we are stead­fast in our com­mit­ment to se­cur­ing the na­tion’s sup­ply con­ti­nu­ity of these crit­i­cal in­jec­tion de­vices,” BD pres­i­dent of med­ica­tion de­liv­ery so­lu­tions Rick Byrd, said in a press re­lease. “Our teams are work­ing tire­less­ly – as they have been since the be­gin­ning of the pan­dem­ic – to en­sure that all of our cus­tomers, in­clud­ing the U.S. gov­ern­ment, have the sup­plies they need to vac­ci­nate against this virus while si­mul­ta­ne­ous­ly man­ag­ing rou­tine, pre­ven­ta­tive health care needs, such as the sea­son­al flu.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER